INTERMOUNTAIN PRECISION GENOMICS WELCOMES TARINELLI AND MOULTON
SALT LAKE CITY, UTAH, USA, October 27, 2015 /EINPresswire.com/ -- Intermountain Precision Genomics announces the addition of Don Tarinelli as the new business development manager and Bryce Moulton as clinical research director.
Tarinelli received his bachelor’s degree in accounting from Utah State University and a master’s degree in business from Utah State University. He will be responsible for developing strategy and leading a team of account managers to promote precision medicine and genomic testing, including genetic sequencing preformed at the Intermountain Precision Genomic Core Laboratory located in St. George, Utah.
Moulton received his bachelor’s degree in biochemistry from Brigham Young University and a master’s degree in business from the University of Utah. Moulton will oversee new experimental research at Intermountain Precision Genomics, broadening the footprint beyond cancer into the fields of neuroscience, cardiovascular, neonatal and other diseases with genetic abnormality associations.
Intermountain Precision Genomics is a service of Intermountain Healthcare which offers genetic sequencing of solid tumors. This in-depth sequencing identifies individual mutations within a person’s cancer cells to identify specific DNA targets for personalized drugs.
For more information about Intermountain Precision Genomics please visit: precisioncancer.org, join the dialog on Facebook (Intermountain Precision Genomics) or follow @precisioncancer on Twitter.
Tarinelli received his bachelor’s degree in accounting from Utah State University and a master’s degree in business from Utah State University. He will be responsible for developing strategy and leading a team of account managers to promote precision medicine and genomic testing, including genetic sequencing preformed at the Intermountain Precision Genomic Core Laboratory located in St. George, Utah.
Moulton received his bachelor’s degree in biochemistry from Brigham Young University and a master’s degree in business from the University of Utah. Moulton will oversee new experimental research at Intermountain Precision Genomics, broadening the footprint beyond cancer into the fields of neuroscience, cardiovascular, neonatal and other diseases with genetic abnormality associations.
Intermountain Precision Genomics is a service of Intermountain Healthcare which offers genetic sequencing of solid tumors. This in-depth sequencing identifies individual mutations within a person’s cancer cells to identify specific DNA targets for personalized drugs.
For more information about Intermountain Precision Genomics please visit: precisioncancer.org, join the dialog on Facebook (Intermountain Precision Genomics) or follow @precisioncancer on Twitter.
Daron Cowley
Intermountain Healthcare
801-442-2834
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.